• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or keep ADHD medication during breastfeeding and pregnancy is a challenge for women suffering from the condition. There aren't enough data regarding how exposure over time may affect the foetus.

A recent study published in Molecular Psychiatry shows that children exposed to ADHD medication during utero do not develop neurological developmental disorders like hearing or vision impairment, febrile seizures, or IQ impairment. The authors acknowledge the need for more high-quality research.

Risk/Benefit Analysis

Pregnant women who use ADHD medications need to balance the advantages of taking them against the potential risks to the foetus. Physicians don't have the information needed to make unequivocal recommendations however they can provide information about risks and benefits that aid pregnant women in making informed decisions.

A study published in Molecular Psychiatry found that women who used ADHD medications during their early pregnancy did not face a significantly higher risk of fetal cardiac malformations or major birth defects that are structural. Researchers used a vast, population-based case-control study to assess the risk of major structural birth defects in infants born to mothers who took stimulants during early pregnancy, and those who did not. Pediatric cardiologists, clinical geneticists and other experts looked over the cases to make sure that the classification was correct and to reduce any bias.

The study of the researchers was not without its limitations. The researchers were not able, in the first place, to separate the effects triggered by the medication from the disorder. This makes it difficult to determine whether the small differences observed in the groups that were exposed result from medication use or comorbidities that cause confusion. Researchers also did not examine the long-term effects for the offspring.

The study showed that babies whose mothers took ADHD medication during pregnancy had a greater risk of being admitted to the neonatal care unit (NICU), compared to those whose mothers did not take any medication during pregnancy, or had discontinued taking their medication prior to or during pregnancy. This increase was due to central nervous system disorders, and the higher risk of admission was not found to be influenced by the stimulant medication was used during pregnancy.

Women who were taking stimulant ADHD medications during pregnancy also had a higher risk of having caesarean sections or one whose baby scored low on the Apgar scale (less than 7). These increases appear to be independent of the type of medication used during pregnancy.

The research suggests that the low risk associated with the use of adhd sleep medication medications during the early stages of pregnancy may be offset by the greater benefits to both mother and child from continued treatment for the woman's disorder. Physicians should discuss this with their patients and, when they are able, assist them in developing strategies to improve coping skills which can reduce the impact of her disorder on her daily functioning and relationships.

Medication Interactions

Many doctors are faced with the decision of whether to maintain treatment or stop it during pregnancy as more women are diagnosed with ADHD. The majority of these decisions are taken in the absence of solid and reliable evidence either way, so physicians must weigh what is the most common adhd medication prescribed they know about their experiences, the experiences of other doctors, and what research suggests about the subject as well as their best judgment for each patient.

In particular, the issue of potential risks to the baby can be tricky. The research on this subject is based on observation rather than controlled studies and many of the findings are in conflict. Most studies focus on live-births, which could underestimate the severity of teratogenic effects that can lead to abortions or terminations of pregnancy. The study that is discussed in this journal club addresses these issues by looking at data from both live and deceased births.

The conclusion The conclusion: While certain studies have demonstrated a positive association between ADHD medications and the risk of certain birth defects, other studies have not found any evidence of a link, and most studies demonstrate a neutral or slightly negative impact. In each case, a careful study of the potential risks and benefits should be conducted.

For a lot of women with ADHD and ADD, the decision to discontinue medication is difficult if not impossible. In a recent article published in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can lead to depression and feelings of isolation. A decrease in medication could also impact the ability to safely drive and to perform work-related tasks which are essential aspects of daily life for those with ADHD.

She suggests that women who aren't sure whether to continue taking the medication or stop due to pregnancy, educate their family members, colleagues, and friends about the condition, the effects on daily functioning, and the advantages of staying on the current treatment regimen. It will also help a woman feel more confident in her decision. Certain medications can be passed through the placenta. If the patient decides to stop taking her ADHD medication while pregnant and breastfeeding, it is crucial to be aware that the drug could be transferred to the infant.

Birth Defects and Risk Types Of Adhd Medication

As the use of ADHD drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases, so do concerns over the impact that these drugs could have on fetuses. A study that was published in the journal Molecular Psychiatry adds to the existing information on this topic. Using two massive data sets, researchers were able to analyze more than 4.3 million pregnancies and determine whether stimulant medication use increased the risk of birth defects. Researchers discovered that, while the risk overall is low, first-trimester ADHD medication use was associated with slightly higher risk of specific heart defects such as ventriculoseptal defect.

The authors of the study found no connection between early medication use and congenital abnormalities like facial clefting, or club foot. The results are in line with previous studies that have shown an insignificant, but small increase in the number of cardiac malformations among women who started taking ADHD medication prior to the time of pregnancy. This risk increased during the latter part of pregnancy, when a lot of women began to stop taking their medication.

Women who took ADHD medications during the first trimester of pregnancy were also more likely to have a caesarean section, a low Apgar score following delivery, and a baby who needed help breathing at birth. However, the authors of the study were not able to eliminate bias due to selection by restricting the study to women who didn't have any other medical issues that could have contributed to the findings.

Researchers hope that their research will inform physicians when they see pregnant women. The researchers advise that while discussing the risks and benefits are important, the choice on whether to continue or stop taking medication should be based on the severity of each woman's ADHD symptoms and her needs.

The authors also caution that, while stopping the medication is an option, it isn't an option to consider due to the high rate of depression and other mental health issues in women who are pregnant or recently post-partum. Furthermore, research suggests that women who choose to stop their medications are more likely to experience difficulties getting used to life without them following the baby's arrival.

Nursing

It can be overwhelming to become a mother. Women with ADHD may face a lot of challenges when they have to manage their symptoms, attend doctor appointments, prepare for the birth of their child and adjust to new routines. As such, many women decide to continue taking their ADHD medication throughout the pregnancy.

The majority of stimulant drugs are absorbed through breast milk in very small amounts, so the risk for infant who is breastfeeding is low. The amount of exposure to medications will vary based on the dosage the medication is administered, its frequency and the time of day. Additionally, different medications enter the body of the baby differently through the gastrointestinal tract and breast milk and the impact of this on a newborn isn't fully understood.

Due to the absence of research, some doctors might be tempted to stop taking stimulant drugs during the course of pregnancy. This is a difficult choice for the patient, who must weigh the benefit of continuing her medication against the possible risks to the embryo. As long as there is no more information, doctors should ask all pregnant patients about their history of ADHD and if they plan or are taking to take medication during the perinatal period.

A increasing number of studies have revealed that most women can safely continue to take their ADHD medication for inattentive adhd and anxiety during pregnancy and while breastfeeding. In response, an increasing number of patients are choosing to do this. They have found, in consultation with their doctor that the benefits of keeping their current medication outweigh any possible risks.

Women who suffer from ADHD who plan to breastfeed should seek the advice of an expert psychiatrist prior to becoming pregnant. They should discuss their medication with their prescriber and discuss the pros and cons of continued treatment, including non-pharmacological strategies. Psychoeducation should also be offered to help pregnant women suffering from ADHD be aware of their symptoms and the underlying disorder and learn about treatment options and strengthen existing strategies for managing. This should include a multidisciplinary approach with the GP, obstetricians and psychiatry. Pregnancy counseling should include a discussion of a treatment plan for the mother as well as the child, as well as monitoring for indicators of deterioration, and, if necessary adjustments to the medication regimen.